LivaNova PLC  

(Public, LON:LIVN)   Watch this stock  
Find more results for Andre Hearty�
-0.23 (-0.44%)
Jul 29 - Close
LON real-time data - Disclaimer
Currency in USD
Range 47.51 - 51.50
52 week 42.45 - 70.00
Open 47.51
Vol / Avg. 164.00/16,888.00
Mkt cap 2.51B
P/E     -
Div/yield     -
EPS -1.73
Shares 49.07M
Beta     -
Inst. own     -
Aug 3, 2016
Q2 2016 LivaNova PLC Earnings Call - 2:00PM GMT+1 - Add to calendar
Aug 3, 2016
Q2 2016 LivaNova PLC Earnings Release - 8:00AM GMT+1 - Add to calendar
Jun 15, 2016
LivaNova PLC Annual Shareholders Meeting
Jun 8, 2016
LivaNova PLC at Goldman Sachs Global Healthcare Conference
May 4, 2016
Q1 2016 LivaNova PLC Earnings Call - Webcast
May 4, 2016
Q1 2016 LivaNova PLC Earnings Release

Key stats and ratios

Q1 (Mar '16) 2015
Net profit margin -13.10% -
Operating margin -12.58% -
EBITD margin - -
Return on average assets -5.84% -
Return on average equity -8.94% -
Employees 4,700 -
CDP Score - -


5 Merchant Square, North Wharf Road
United Kingdom - Map
+44-20-37865275 (Phone)

Website links

External links

Analyst Estimates - BusinessWeek
Options - MarketWatch
Director Dealings - Yahoo Finance


LivaNova PLC is a United Kingdom-based medical technology company. The Company focuses on providing treatment for cardiovascular diseases and neuromodulation. The Company operates under three business units: Cardiac Rhythm Management, Cardiac Surgery and Neuromodulation. The Company provides solutions for patients, healthcare professionals and healthcare systems. The Company's Cardiac Rhythm Management unit focuses on Bradyarrhythmia, Tachyarrhythmia, Heart Failure, Arrhythmia Assessment and Electrophysiology. The Company's Cardiac Surgery unit focuses on Aortic, Mitral, Perfusion, Cannulae, Minimally Invasive Cardiac Surgery and Pediatric. Its Neuromodulation unit focuses on providing medical device solutions for people affected by treatment-resistant epilepsy, depression, heart failure and other chronic disorders. Its products include PARADYM RF, VOLTA, SMARTVIEW, SOLO SMART, CONNECT, INSPIRE, XTRA, MINIMALLY INVASIVE CARDIAC SURGERY CANNULAE and PEDIATRIC CANNULAE, among others.

Officers and directors

Andre-Michel Ballester Chief Executive Officer, Executive Director
Age: 48
Vivid Sehgal Chief Financial Officer
Michel Darnaud President - Cardiac Surgery
Stefano Di Lullo President - Cardiac Rhythm Management
Jacques Gutedel President - Intercontinental
Age: 56
Rohan H. Hoare Ph.D. President - Neuromodulation
Age: 50
Brian Sheridan Senior Vice President, General Counsel, Company Secretary
David S. Wise Senior Vice President - Human Resources & Information Technology
Edward Andrle Senior Vice President - Strategy & Business Development
Pritpal Shinmar Senior Vice President - Global Market Access